Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
Date:3/12/2009

Keryx to Host Investor Conference Call on Friday, March 13, 2009 at 8:30am EDT

NEW YORK, March 12 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer (the "Company"), today announced its results for the fourth quarter and year ended December 31, 2008.

At December 31, 2008, the Company had cash, cash equivalents, short-term investment securities and interest receivable of $15.5 million, as compared to $62.4 million at December 31, 2007. In addition, at December 31, 2008, the Company had $7.2 million of auction rate securities which are classified as long-term investments.

The net loss for the fourth quarter ended December 31, 2008 was $3,807,000, or $0.08 per share, compared to a net loss of $29,261,000, or $0.67 per share, for the comparable quarter in 2007, representing a decrease in net loss of $25,454,000. The decrease in net loss was primarily attributable to a $14,076,000 decrease in research and development expenses related to the cessation of the development of Sulonex in March 2008, a $7,013,000 and $2,735,000 decrease in research and development expenses related to KRX-0401 and Zerenex, respectively, a $1,385,000 decrease in other selling, general and administrative expenses, and a $562,000 decrease in non-cash compensation expense related to equity incentive grants, partially offset by a $1,011,000 decrease in interest and other income (expense), net.

The net loss for the year ended December 31, 2008 was $52,881,000, or $1.18 per share, compared to a net loss of $90,062,000, or $2.07 per share, for the year ended December 31, 2007, represe
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
2. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
4. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... Belgium , Nov. 24, 2014 ... on developing diagnostic tests for cancer and other conditions, today ... be presented at the Science for Business BioWin Day 2014, ... . The data come from VolitionRx,s lung cancer pilot ... department of the Centre Hospitalier Universitaire (CHU) de Liege in ...
(Date:11/24/2014)... 2014 Deep Research Report on Global ... and in-depth research report on the Adipic Dihydrazide ... definition, classification, application, and industry chain structure as ... international market analysis, including China’s domestic market as ... Asia, China, Japan etc. regions) industry analysis covering ...
(Date:11/22/2014)... 2014 Two new educational webinars hosted by ... for ALS research and how the pharmaceutical industry can make ... Bucket Challenge: Where Does the ALS Money Go? , Featuring ... 2014, Time: 1:30pm ET, Register to attend , ... Merit Cudkowicz, Julianne Dorn Professor of Neurology at Massachusetts General ...
(Date:11/22/2014)... On November 17th Chicago start-up Briteseed ... Medical Technologies Summit in San Francisco to take first ... among Silicon Valley investors and technology elites as the ... also positions Briteseed to move on to the ... and compete with other elite innovation finalists for a ...
Breaking Biology Technology:VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 4VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 5VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 6Adipic Dihydrazide Industry 2019 Research Forecasts on Worldwide, China Regions Now Available at ReportsnReports.com 2Adipic Dihydrazide Industry 2019 Research Forecasts on Worldwide, China Regions Now Available at ReportsnReports.com 3DrugDev Webinars in December to Explore What Comes Next for ALS Research and How We Can Make Life Easier for Clinical Sites 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 3
... Third Quarter Net Revenues Up 98% and Adjusted ... 12 /Xinhua-PRNewswire/ -- WuXi PharmaTech,(Cayman) Inc. (NYSE: ... research and development outsourcing company with operations,in China ... financial,results for the third quarter ended September 30, ...
... Beckman,Coulter, Inc. (NYSE: BEC ), a ... simplify, automate, and innovate complex biomedical,testing, announced ... vice,president and chief financial officer, will present ... Conference on Tuesday, November 18, 2008 at,4:40 ...
... LINCOLN, Neb., Nov. 12 Protease substrates provide ... of inhibitors,and screen compound collections for discovery of ... NIR-FRET Protease Substrates:,IRDye 800CW/QC-1 HIV-1, IRDye 800CW/QC-1 BACE, ... low intrinsic fluorescence due to self-quenching,of the conjugated ...
Cached Biology Technology:WuXi PharmaTech Announces Third Quarter 2008 Results 2WuXi PharmaTech Announces Third Quarter 2008 Results 3WuXi PharmaTech Announces Third Quarter 2008 Results 4WuXi PharmaTech Announces Third Quarter 2008 Results 5WuXi PharmaTech Announces Third Quarter 2008 Results 6WuXi PharmaTech Announces Third Quarter 2008 Results 7WuXi PharmaTech Announces Third Quarter 2008 Results 8WuXi PharmaTech Announces Third Quarter 2008 Results 9WuXi PharmaTech Announces Third Quarter 2008 Results 10WuXi PharmaTech Announces Third Quarter 2008 Results 11WuXi PharmaTech Announces Third Quarter 2008 Results 12WuXi PharmaTech Announces Third Quarter 2008 Results 13LI-COR Introduces Three IRDye(R) Near-Infrared Fluorescence Resonance Energy Transfer (NIR-FRET) Protease Substrates 2
(Date:11/21/2014)...   Atmel® Corporation (NASDAQ: ATML ... technology solutions, today launched the industry,s first family of ... V cc range from 1.7V to 5.5V. The ... 2 C bus communication speeds, and are available with ... ideal for consumer, industrial, computer, and medical applications. ...
(Date:11/18/2014)... 2014 The Parenteral Drug Association (PDA) today confirmed ... speak and at least seven more will participate in the ... Shoreham Hotel in Washington D.C. , Dec. ... significant support from the regulatory agencies in the ... in our effort to help advance the use of metrics ...
(Date:11/12/2014)... PALM BEACH GARDENS, Fla. , Nov. 12, 2014 ... management solutions, announced today that its U.are.U ® ... upscale retail bakery chain in Central Mexico ... solution in June 2014 to eliminate payroll issues caused ... Prior to installing the U.are.U fingerprint readers, Montparnasse ...
Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... Biomedical and Chemical Engineering at L.C. Smith College of ... commonly used nanoparticles, particles up to one million times ... damage cell membranes. In a recent article ... Langmuir entitled "Effects of nanoparticle charge and ...
... A study led by Robert G. Hawley, Ph.D., ... and regenerative biology at the George Washington University ... may help predict which patients with multiple myeloma ... titled "Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma ...
... MA) -- Microbiologists who study wild marine microbes, as opposed ... clear picture of the daily activities of their subjects. But ... Aquarium Research Institute recently figured out how to make the ... many coexisting species in their native habitat over time. ...
Cached Biology News:Modifications of a nanoparticle can change chemical interactions with cell membranes 2New research may aid treatment of multiple myeloma patients 2New research may aid treatment of multiple myeloma patients 3Microbiologists eavesdrop on the hidden lives of microbes 2Microbiologists eavesdrop on the hidden lives of microbes 3
... Helios gene gun system, 100-120 V, is ... into cells. This handheld device employs an ... and other biomaterial-coated gold microcarriers from the ... directly into target cells. This system has ...
... Clean and Accurate Results Laser Capture ... the sensitivity and accuracy of molecular assays ... types and multi-cellular structures isolated from whole ... to microdissection-developed in 1996 at the National ...
...
Mouse monoclonal antibody raised against a partial recombinant DHX8. NCBI Entrez Gene ID = DHX8...
Biology Products: